Europe's First New Gut Treatment in a Decade Just Cleared a Major Hurdle

The practical goal? Reduce how much IV nutrition patients need each week, or in some cases, eliminate it entirely.

The Data Behind the Decision

The CHMP's recommendation was based primarily on the Phase 3 EASE-1 trial, with supporting data from three additional studies (EASE-2, EASE-3, and EASE-4). The headline result tells a clear story.

Patients receiving twice-weekly glepaglutide reduced their weekly parenteral support by 5.13 liters, compared to just 2.85 liters in the placebo group. That difference was statistically significant (p=0.0039), which in clinical-trial speak means it almost certainly wasn't a fluke.

But the numbers that really matter for patients are the practical ones. About 66% of patients on twice-weekly glepaglutide cut their IV nutrition volume by at least 20%. Compare that to roughly 39% on placebo. And more than half of treated patients dropped at least one full day of parenteral support per week.

For anyone who has spent years tethered to an IV pole multiple nights a week, losing even a single session is life-changing. Perhaps most striking: five patients in the treatment group were weaned off parenteral support completely. Zero patients on placebo achieved that.

Why This Is a Bigger Deal Than It Looks

SBS is rare. It's not going to generate Ozempic-level revenue. Zealand Pharma isn't about to become the next Novo Nordisk on the back of this drug alone.

But that's not the point.

For the European SBS community, this is the first significant new treatment option in over a decade. The current standard of care isn't really a "treatment" at all; it's managing the condition through lifelong parenteral nutrition. There's no crowded competitive landscape of branded SBS drugs in Europe. There's essentially a void.

Zeydovio fills that void with a twice-weekly injection that demonstrably reduces (and sometimes eliminates) the need for IV nutrition. For rare disease markets, that kind of unmet need is exactly what regulators love to see.

The Commercial Question Mark

Of course, getting a positive CHMP opinion and actually selling a drug in Europe are two very different things. European pricing and reimbursement happen country by country, which means Zealand will need to negotiate with individual national health authorities across the continent. For orphan drugs (rare disease treatments), those negotiations can be long and unpredictable.

No pricing details have been disclosed yet, and they won't be until after the European Commission grants final authorization and country-level talks begin. The small patient population cuts both ways: it limits the total market size, but it also gives Zealand leverage to seek premium orphan-drug pricing.

Zealand's Bigger Picture

Zeydovio isn't Zealand Pharma's only bet. The Danish company has been aggressively building out what it calls its "Metabolic Frontier 2030" plan, targeting five products on the market and ten clinical programs in development by the end of the decade.

The crown jewel of that pipeline is petrelintide, an obesity candidate being co-developed with Roche. Zealand confirmed plans to launch a registrational Phase 3 program for petrelintide as a standalone therapy, plus a Phase 2 combination study. The Roche partnership covers co-development and co-commercialization in both the U.S. and Europe, which is a significant financial backstop for a company Zealand's size.

Financially, the company has held its 2026 guidance steady: DKK 4.5 billion in collaboration revenue and DKK 2.7 to 3.3 billion in operating expenses. Not every analyst is thrilled, though. Barclays recently cut its rating on Zealand, citing "distant catalysts," a polite way of saying the biggest payoffs are still years away.

That's fair criticism. But Zeydovio's European trajectory is the opposite of distant. It's happening right now.

What Comes Next

The European Commission has roughly two months to issue its final decision. Barring something truly unexpected, Zeydovio should receive marketing authorization before the year is out. After that, the real work begins: negotiating reimbursement deals, building out commercial infrastructure, and getting the drug into the hands of the patients who need it most.

For the rare disease world, this is a meaningful win. For Zealand Pharma, it's proof that the company can take a molecule from lab bench to regulatory finish line in one of the world's toughest markets. And for SBS patients across Europe who've spent years managing their condition with IV bags and infusion pumps, it's something even better.

It's an option they didn't have before.

AstraZeneca's Breast Cancer Pill Had One Job. It Didn't Deliver.

AstraZeneca's oral breast cancer pill camizestrant missed its primary endpoint in the pivotal SERENA-4 trial, failing to prove a statistically significant benefit in first-line advanced breast cancer. The setback narrows the drug's commercial ceiling just as Eli Lilly's competing therapy racks up its second FDA approval.